Brief: Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001
19/08/2024 13:17
Aug 19 (Reuters) - Alzamend Neuro Inc ALZN.O :
* ALZAMEND NEURO PARTNERS WITH MASSACHUSETTS GENERAL
HOSPITAL FOR
A PHASE II CLINICAL TRIAL OF AL001, A NEXT-GENERATION LITHIUM
THERAPEUTIC DRUG CANDIDATE, INVOLVING PATIENTS WITH
POST-TRAUMATIC STRESS DISORDER
Source text for Eikon: ID:nBwbV2Zbpa
Further company coverage: ALZN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview